APIRx-1601 is under clinical development by Incannex Healthcare and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the APIRx-1601 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APIRx-1601 overview
APIRx-1601 is under development for the treatment of skin vitiligo. The drug candidate is a cannabinoid product. The drug candidate is a combination of Cannabigerol (CBG) and Cannabidiol (CBD). It acts by targeting cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).
Incannex Healthcare overview
Incannex Healthcare, is a pharmaceutical company. The company offers the development and manufacturing of cannabinoid medicine and therapeutic products. Its product portfolio includes releafia, nutralesic, inflammex, and cannagesia. Incannex Healthcare products are used in the treatment of obstructive sleep apnea, traumatic brain injury, sepsis-associated acute respiratory distress syndrome, and temporomandibular joint dysfunction. It also provides clinical trials and research and development services. It operates in Australia and New Zealand. Incannex Healthcare is headquartered in Melbourne, Victoria, Australia.
For a complete picture of APIRx-1601’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
